In conclusion, these findings validate PPARγ as a targetable conduit in triple-negative and ER-positive breast cancers and open new opportunities for co-targeting PPARγ and HDACs using repurposed anti-diabetic (rosiglitazone) and anti-myeloma/lymphoma (LBH589 and SAHA) drugs. This evidence concerns the gene PPARG and plasma cell myeloma.